Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

In development [GID-DG10015] Expected publication date: 09 May 2018

Register as a stakeholder

Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10): Diagnostics consultation

The National Institute for Health and Care Excellence (NICE) is producing guidance on using tumour profiling tests (EndoPredict, MammaPrint, Oncotype DX Breast Recurrence Score, Prosigna and IHC4+C) to guide adjuvant chemotherapy decisions in people with breast cancer in the NHS in England. The diagnostics advisory committee has considered the evidence base and the views of clinical and patient experts.

The advisory committee is interested in receiving comments on the following:

Has all of the relevant evidence been taken into account?
Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
Are the provisional recommendations sound, and a suitable basis for guidance to the NHS?

Equality issues

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the preliminary recommendations may need changing in order to meet these aims. In particular, please tell us if the preliminary recommendations:

could have a different effect on people protected by the equality legislation than on the wider population, for example by making it more difficult in practice for a specific group to access the technology
could have any adverse effect on people with a particular disability or disabilities.

Please provide any relevant information or data you have regarding such effects and how they could be avoided or reduced.

Note that this document is not NICE's final guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer. The recommendations in section 1 may change after consultation.

We are also updating the guideline on early and locally advanced breast cancer. See the guidance in development page for more information about the update.

After consultation, the committee will meet again to consider the evidence, this document and comments from the consultation. After considering these comments, the committee will prepare its final recommendations, which will be the basis for NICE’s guidance on the use of the technology in the NHS in England.

For further details, see the Diagnostics Assessment Programme manual

Key dates:

Closing date for comments: 31 January 2018